Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures
Intra-tumor heterogeneity represents a major barrier to anti-cancer therapies. One strategy to minimize this limitation relies on bystander effects via diffusion of cytotoxins from targeted cells. Hypoxia-activated prodrugs (HAPs) have the potential to exploit hypoxia in this way, but robust methods...
Main Authors: | Cho R. Hong, Gib Bogle, Jingli Wang, Kashyap Patel, Frederik B. Pruijn, William R. Wilson, Kevin O. Hicks |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01013/full |
Similar Items
-
The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104
by: Annika eFoehrenbacher, et al.
Published: (2013-10-01) -
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
by: Maria R. Abbattista, et al.
Published: (2021-11-01) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
by: Yue Li, et al.
Published: (2021-07-01) -
The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy
by: David F. Ackerley, et al.
Published: (2013-08-01) -
Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System
by: Abigail V. Sharrock, et al.
Published: (2021-06-01)